”The study proves the potential of SyMRI® IMAGE to become a standard method for conducting neuro scans in a fraction of time and in helping clinicians diagnosing patients”, says Stefan Tell, CEO of SyntheticMR.
The study comprising a set of 1526 images were read by 7 neuroradiologists comparing synthetic and conventional MR brain images from 109 subjects with neuroimaging indications. The results revealed that the diagnostic quality of the images generated synthetically were non-inferior to conventional imaging.
MAGiC (Magnetic Resonance Image Compilation) is the industry’s first multi-contrast magnetic resonance (MR) technique cleared with the U.S. FDA. The technique gives clinicians more data than conventional scanning in a substantially shorter time frame*. MAGiC gives users the flexibility to adjust the images retrospectively leading to significant timesaving, fewer rescans and therefore cost savings, which combined, can assist the clinician in making a more decisive diagnosis.
For additional information, please contact Stefan Tell, CEO, +46 73 373 40 90 or Jonas Hurtig, Head of Marketing and Commercial Affairs, +46 76 311 61 14.
* Based on MAGiC clinical study of 109 patients from 6 separate institutions.
The study can be acquired on http://www.ajnr.org/content/early/2017/04/27/ajnr.A5227
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI® delivering multiple, adjustable contrast images and quantitative data from a single 5-6 minute scan – generating increased patient throughput and objective decision support for clinicians. SyMRI is a CE-marked product and is FDA 510(k) pending. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com